US-based pharmaceutical company, Antares Pharma has received additional regulatory approvals in Australia for use of ‘Zomacton’. The company’s license partner Ferring Pharmaceuticals has received the approvals.
Zomacton is Antares' needle-free injection device with the human growth hormone (hGH). Australia's regulatory agency for drugs and devices, Therapeutic Goods Administration (TGA) has approved applications filed by Ferring for ‘Zomajet 2 Vision’ and ‘Vision X’ needle-free devices. The application also includes the associated consumables, to be used with Zomacton in both the 4mg and 10mg formulations.
"We are pleased that Ferring continues to expand into new markets and is introducing the ‘Vision X’ device for use with their ‘Zomacton’ 10mg product. The combination of the higher strength formulation with Antares' proprietary needle-free system will continue the focus for both companies of enhancing patient compliance and convenience with self administration of hGH," said Dr Paul Wotton, President and CEO, Antares.